229 Results for "

cMyc

" in MedChemExpress (MCE) Product Catalog:
Products (229)

229 Results for "cMyc" in MCE Product Catalog:

  • Targets Recommended:
60
60 Publications Verification
Referencia número: HY-12702
No. CAS: 403811-55-2
Pureza:  99.49%
Target:  

c-Myc Autophagy

Áreas de investigación:  

Cancer

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
loading...
    loading...
22
22 Cited Publications
Referencia número: HY-107738
No. CAS: 95975-55-6
Pureza:  99.81%
Synonyms: Z/E-Guggulsterone
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC50s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .
loading...
    loading...
21
21 Cited Publications
Referencia número: HY-16291
No. CAS: 916151-99-0
Synonyms: LOR-253; LT-253
Target:  

c-Myc KLF Apoptosis

Áreas de investigación:  

Inflammation/Immunology Cancer

APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .
loading...
    loading...
19
19 Cited Publications
Referencia número: HY-17381A
No. CAS: 58957-92-9
Synonyms: 4-Demethoxydaunorubicin
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts .
loading...
    loading...
17
17 Cited Publications
Referencia número: HY-13241
No. CAS: 862507-23-1
Pureza:  99.94%
Synonyms: LY2228820 dimesylate
Áreas de investigación:  

Inflammation/Immunology Cancer

Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
loading...
    loading...
12
12 Cited Publications
Referencia número: HY-15594A
No. CAS: 929895-45-4
Pureza:  98.99%
Synonyms: Phen-DC3 Triflate
Phen-DC3 Trifluoromethanesulfonate is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 Trifluoromethanesulfonate selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 Trifluoromethanesulfonate also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 Trifluoromethanesulfonate can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury .
loading...
    loading...
8
8 Cited Publications
Referencia número: HY-145669
No. CAS: 113411-17-9
Pureza:  99.84%
Target:  

Wnt CDK GSK-3

Áreas de investigación:  

Infection Cancer

DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .
loading...
    loading...
7
7 Cited Publications
Referencia número: HY-P80626
Synonyms: MYC; BHLHE39; Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64

Host:  

Rabbit

Application:  

WB, ICC/IF, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
5
5 Cited Publications
Referencia número: HY-100669
No. CAS: 944547-46-0
Pureza:  98.11%
Target:  

c-Myc Autophagy

Áreas de investigación:  

Cancer

Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .
loading...
    loading...
5
5 Cited Publications
Referencia número: HY-N0330
No. CAS: 96990-18-0
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
loading...
    loading...
4
4 Cited Publications
Referencia número: HY-120929
No. CAS: 1875036-74-0
Pureza:  98.28%
Target:  

E1/E2/E3 Enzyme c-Myc

Áreas de investigación:  

Inflammation/Immunology Cancer

BI8622 is a specific inhibitor of the ubiquitin ligase HUWE1 with an IC50 of 3.1 μM. BI8622 can decrease the protein expression levels of c-myc and glycolytic markers as well as immune modulatory markers after HUWE1 inhibition in triple-negative breast cancer (TNBC) cell lines. BI8622 significantly protects against cisplatin (HY-17394)-induced acute kidney injury (AKI). BI8622 significantly reduces the growth of multiple myeloma (MM) cell lines and induces cell cycle arrest. BI8622 can prevent HUWE1-dependent TTBK2 ubiquitination. BI8622 can be studied in research for various diseases including medulloblastoma, acute kidney injury, breast cancer and MM .
loading...
    loading...
3
3 Cited Publications
Referencia número: HY-126477
No. CAS: 64091-91-4
Pureza:  99.98%
NNK is a nicotine-nitrosated derivative. NNK simultaneously stimulates Bcl2 phosphorylation exclusively at Ser 70 and c-Myc at Thr 58 and Ser 62 through activation of both ERK1/2 and PKCα . NNK induces survival and proliferation of human lung cancer cells. NNK can be used for lung cancer mice model structure .
loading...
    loading...
3
3 Cited Publications
Referencia número: HY-148333
No. CAS: 2225938-86-1
Pureza:  98.00%
Áreas de investigación:  

Cancer

MS177 is an effective and fast-acting EZH2 degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC50): 12 nM). MS177 effectively depletes both canonical EZH2-PRC2 and noncanonical EZH2-cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .
loading...
    loading...
3
3 Cited Publications
Referencia número: HY-19759
No. CAS: 1001908-89-9
Target:  

Sirtuin Apoptosis

Áreas de investigación:  

Cancer

SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM . SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-134761
No. CAS: 1197824-15-9
Pureza:  96.29%
Target:  

c-Myc

Áreas de investigación:  

Cancer

EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-109050
No. CAS: 1637771-14-2
Pureza:  98.04%
Synonyms: GS-5829
Áreas de investigación:  

Cancer

Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-111411
No. CAS: 2223019-53-0
Pureza:  99.74%
Target:  

c-Myc Autophagy

Áreas de investigación:  

Cancer

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-12703
No. CAS: 1151813-61-4
Pureza:  98.94%
Target:  

c-Myc Autophagy

Áreas de investigación:  

Cancer

KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-P700468
Pureza:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rHuGlucagon-like peptide 1 receptor/GLP1R, Fc; Glucagon-like peptide 1 receptor; GLP-1 receptor; GLP-1-R
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Referencia número: HY-103019
No. CAS: 1610408-97-3
Pureza:  99.89%
Synonyms: (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib
Áreas de investigación:  

Inflammation/Immunology Cancer

Enitociclib ((+)-BAY-1251152; (+)-VIP152) is a selective CDK9 inhibitor (IC50=3 nM) that inhibits transcriptional elongation by blocking Ser2/Ser5 phosphorylation of RNA polymerase II. Enitociclib specifically depletes key short-lived proteins such as c-MYC, MCL-1 and induces tumor cell apoptosis. Enitociclib also interferes with the production of enhancer RNAs (eRNA) and enhancer-promoter interactions, and downregulates oncogene expression at the epigenetic level. Enitociclib exerts synergistic effects with agents including Bortezomib (HY-10227), Lenalidomide (HY-A0003), Pomalidomide (HY-10984), Venetoclax (HY-15531) and Paclitaxel (HY-B0015), and even reverses paclitaxel resistance. Enitociclib serves as a vital research tool for various malignancies such as double-hit diffuse large B-cell lymphoma, multiple myeloma and pancreatic ductal adenocarcinoma .
loading...
    loading...